Unlock instant, AI-driven research and patent intelligence for your innovation.

Compound and method of treatment for fungal pathologies of the oral cavity

Inactive Publication Date: 2005-10-20
ZENGEN
View PDF8 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0013] In another preferred embodiment of the invention these peptides are topically or systemically applied to treat a candida infection of the oral cavity. In yet another embodiment of the invention these peptid

Problems solved by technology

Chronic candidiasis is both far more common and far more difficult to treat than thrush.
However, a close-fitting upper denture creates a microenvironment cut-off from any protective effects of saliva.
During treatment, the dentures must be worn as little as possible to allow the drug to the reach affected area, thus, inconveniencing suffering denture wearers.
Treatment of candidal leuloplakia infections is difficult since the intracellular growth of the candida makes it less accessible to antifungal drugs.
Absent treatment, these leukoplakias often cover large areas of the mouth and tongue, making eating painful and causing significant social anxiety among the afflicted.
Its lesions may extend down the pharynx or larynx and when affecting the mouth and lips, can be severely disfiguring.
Treatment for all these candidal immune disorders is difficult.
If the immunological defect can be identified, as is sometimes the case with diffuse chronic mucocutaneous candidiasis, treatment may be possible, but generally treatments are ineffective because they fail to address the underlying immunological disorder that allows the candida to flourish.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound and method of treatment for fungal pathologies of the oral cavity
  • Compound and method of treatment for fungal pathologies of the oral cavity
  • Compound and method of treatment for fungal pathologies of the oral cavity

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0040] The first example suggests that α-MSH (11-13) (SEQ ID NO: 1), (6-13) (SEQ ID NO: 2) and (1-13) (SEQ ID NO: 3) exhibit similar anti-candidal properties as flucanazole over an exceedingly broad range of concentrations.

[0041]C. albicans (1×106 / ml in HBSS) was incubated in the presence of absence or α-MSH (1-13) (SEQ ID NO: 3) or (11-13) (SEQ ID NO: 1) at concentrations in the range of 10−15 M to 10−6 M for 2 hours at 37° C. Cells were then washed in cold distilled waste and diluted with HBSS to a concentration of 100 organisms / ml. One-ml aliquots were dispensed on blood agar plates and incubated for 48 hours at 37° C. Organism viability was estimated from the number of colonies formed.

[0042] In subsequent experiments using familiar procedures we compared activity of α-MSH (4-10) (SEQ ID NO: 5), (6-13) (SEQ ID NO: 2), (11-13) (SEQ ID NO: 1), ACTH (1-39) (SEQ ID NO: 6), (18-39) (SEQ ID NO: 7) and fluconazole, the latter an established antifungal agent. Melanocortin peptides and ...

example 2

[0046] Example 2 demonstrates that α-MSH (1-13) (SEQ ID NO: 3), (6-13) (SEQ ID NO: 2) or (11-13) (SEQ ID NO: 1) strongly inhibits Candidal germination. C. albicans from stationary phase cultures were washed twice with distilled water and suspended in HBSS to a final concentration of 2×10−6 / ml. Hyphal growth was induced by addition of 10% inactivated horse serum (GIBCO / BRL, Great Britain) to yeast incubated for 45 minutes at 37° C. with continuous shaking. Horse serum was removed by washing cells twice with HBSS and incubation was continued for 60 minutes at 37° C. in the presence of α-MSH (1-13)_(SEQ ID NO: 3), (6-13) (SEQ ID NO: 2) or (11-13) (SEQ ID NO: 1) at a concentration of 10−6M with continuous shaking. The percentage of filamentous cells was evaluated under a light microscope with the aid of hemocytometer. Experiments were run in triplicate and at least 200 cells were scored. Photomicrographs were taken with a MC100 camera attached to an Axioskop Zeiss microscope.

[0047] FIG...

example 3

[0049] Example 3 illustrates that α-MSH and its derivatives exhibit their anti-candidal properties without compromising the ability of human neutrophils to independently combat Candida. Venous blood (20m1) from health volunteers was anticoagulated with heparin. Neutrophils were isolated using dextran sedimentation and Ficoll-Hypaque (Sigma Chemical Co., St. Louis, Mo., USA) centrifugation. Erythrocytes were lysed via hypotonic shock. Neutrophils represented at least 97% of the cell suspension. Cell viability, estimated by trypan blue exclusion, was>98%. Neutrophils were suspended to a final concentration in HBSS.

[0050]C. albicans (1×10−6) were opsonized with human AB serum in a shaking water bath for 30 minutes at 37° C. Organisms were then incubated with neutrophils in medium or in medium with α-MSH (1-13) (SEQ ID NO: 3) or (α-MSH (11-13) (SEQ ID NO: 1) in concentrations of 10×15 M to 10−4 M in a shaking water bath for 2 hours at 37° C. After incubation, the culture tubes were pla...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Molar densityaaaaaaaaaa
Compositionaaaaaaaaaa
Concentrationaaaaaaaaaa
Login to View More

Abstract

The broadest aspect of the invention is a composition and method of treatment of fungal pathologies of the oral cavity or fungal growth on the surface of dentures. A preferred embodiment of the is a pharmacologically effective amount of a peptide selected from the group of peptides with a C-terminal sequence consisting of KPV, HFRWGKPV, and SYSMEHFRWGKPV in combination with a therapeutically effective amount of a fungicide selected from the group consisting of: itraconazole, econazole, ketoconazole, miconazole and fluconazole. Another embodiment of the invention is a method for treating fungal pathologies of the of oral cavity and dentures by application of a pharmacologically effective amount of a peptide selected from the group of peptides with a C-terminal sequence consisting of KPV, HFRWGKPV, and SYSMEHFRWGKPV in combination with a therapeutically effective amount of a fungicide selected from the group consisting of itraconazole, econazole, ketoconazole, miconazole and fluconazole. In yet another embodiment of the invention these peptides are used in combination with a therapeutically effective amount of gram positive and / or gram negative antibiotics.

Description

PRIORITY CLAIM [0001] This application claims priority to U.S. patent application Ser. No. 09 / 774,282 filed on Jan. 29, 2001, and now pending, and is incorporated herein by reference, including all drawings, figures and cited references.BACKGROUND OF THE INVENTION [0002] This invention relates to the field of pathologies of the oral cavity caused by fungi. [0003] One of the most common and stubborn infections of the mouth and throat is Candidiasis. Thrush or acute candidiasis is caused by extensive candidal invasion of the oral mucosal epithelium. Thrush presents as creamy, yellow tufts which can be readily wiped off with a swab to expose a red and inflamed area of epithelium. The cottony tufts are the result of extensive infiltration of candidal hyphae into the mucosal epithelium. [0004] Although thrush is most common in infants, it also occurs in adults that are immunocompromised, undergoing broad spectrum antibiotic treatment, undergoing corticosteroid treatment, diabetics and an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/00A61K31/00A61K38/00A61K45/06
CPCA61K9/006A61K31/00A61K45/06A61K38/35A61K38/34A61K2300/00A61P31/10
Inventor LIPTON, JAMESCATANIA, ANNA
Owner ZENGEN